Opiant Pharmaceuticals, Inc.
If you purchased Opiant Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
OPNT STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF OPIANT PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS
November 14, 2022.
New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) to Indivior PLC is fair to Opiant shareholders. Per the agreement, Indivior would acquire Opiant for $20.00 per share in cash, plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch.
The investigation concerns whether Opiant and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Opiant shareholders; (2) determine whether Indivior is underpaying for Opiant; and (3) disclose all material information necessary for Opiant shareholders to adequately assess and value the merger consideration. On behalf of Opiant shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.